Benchmark Reiterates Buy Rating on Halozyme Therapeutics (HALO) on 'Solid Partnership Momentum'
Go back to Benchmark Reiterates Buy Rating on Halozyme Therapeutics (HALO) on 'Solid Partnership Momentum'| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 100.67 -1.12 (1.1%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $101.79 | 52 Week High | $18.39 | |||
| Open | $101.95 | 52 Week Low | $6.96 | |||
| Day High | $102.40 | P/E | N/A | |||
| Day Low | $99.41 | EPS | $-0.58 | |||
| Volume | 1,982,781 | |||||
